GlassScriptPhysician profile
Mark I Ohriner
NPI 1922053784
$5,649.53
in general payments reported to CMS, 2019-2025
26 companies · $545 in 2025
The $545 reported for 2025 was more than what 79% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $705 · 2021: $1,119 · 2022: $323 · 2023: $801 · 2024: $600 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $837.15 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $556.26 | 2019-2023 | Cequa |
| Novartis Pharmaceuticals Corporation | $499.49 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $444.22 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $429.82 | 2024-2025 | Xdemvy |
| Mallinckrodt Enterprises LLC | $347.90 | 2019 | |
| Bausch & Lomb Americas INC. | $342.68 | 2023-2025 | Xiidra, Miebo |
| Alcon Vision LLC | $201.84 | 2019-2024 | Rocklatan |
| Dompe US, INC. | $180.25 | 2019 | |
| Coopervision INC. | $178.97 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens |
| Mallinckrodt Hospital Products INC. | $149.53 | 2020 | |
| Sight Sciences, INC. | $132.38 | 2023 | Omni Surgical System |
| Abbvie INC. | $129.69 | 2023 | |
| Shire North American Group INC | $123.60 | 2019 | |
| Harrow Eye, LLC | $121.96 | 2025 | Vevye |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $121.83 | 2025 | Tepezza |
| Apellis Pharmaceuticals, INC. | $121.81 | 2023 | Syfovre |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $119.69 | 2019 | |
| Eyepoint US, INC. | $117.81 | 2020 | |
| Aerie Pharmaceuticals, INC. | $111.66 | 2020 | |
| Kala Pharmaceuticals, INC. | $111.07 | 2021 | |
| Alcon Research LLC | $102.29 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $93.62 | 2019-2024 | Acuvue |
| Synergeyes, INC. | $28.07 | 2019 | |
| Allergan, INC. | $27.01 | 2021 | |
| Biotissue Holdings INC. | $18.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ohriner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.